OS Therapies completes acquisition of Advaxis Immunotherapies clinical, pre-clinical and IP assets from Ayala Pharmaceuticals

CAR-T Digest - August 2020

09 Apr 2025: OS Therapies completes acquisition of Advaxis Immunotherapies clinical, pre-clinical and IP assets from Ayala Pharmaceuticals

OS Therapies (NYSE-A: OSTX) has completed the acquisition of listeria-based cancer immunotherapy assets from Ayala Pharmaceuticals’ Advaxis Immunotherapies, enhancing its clinical-stage pipeline focused on immunotherapy and ADCs
The company’s lead asset, OST-HER2, targets recurrence prevention in fully-resected, lung metastatic osteosarcoma and is expected to reach the market by year-end 2025
OS Therapies now owns a broad pipeline, including late, mid, and early-stage immunotherapy candidates, along with preclinical programs like 8 OST-HOT constructs for off-the-shelf cancer treatment
The listeria-based platform is protected by new manufacturing-related intellectual property through 2040, securing long-term competitive advantage
Acquired assets include OST-AXAL for HPV-associated cancers (completed one of two Phase 3 trials), OST-503 with positive Phase 2 results in NSCLC and OST-PSA for prostate cancer